

APC Newsletter



Northern Lincolnshire Area Prescribing Committee

Introduction

The APC would like to identify clinicians from both primary and secondary care who are willing to support the creation of a Shared Care Guideline for DMARDs. Interested parties are requested to contact Richard Neilson on 07780 811 118 in the first instance.

See the new Diabetes Pathway, accessed via the Formulary on the APC website.

New Patient Treatments

The following medicines have been added to Formulary Chapter 5.3.1 and will be used for HIV:

Emtricitabine (all common forms) - a nucleoside reverse transcriptase inhibitor. Brand name Emtriva.

Trizivir tablets - a combination of abacavir, lamivudine and zidovudine.

Efavirenz (all common forms) - a non-nucleoside reverse transcriptase inhibitor. Brand name Sustiva.

Etravirine tablets - a non-nucleoside reverse transcriptase inhibitor. Brand name Intelence.

Rilpivirine tablets - a non-nucleoside reverse transcriptase inhibitor. Brand name Edurant.

Other specialist initiated products added to the Northern Lincolnshire Formulary are:

Lisdexamfetamine for ADHD, added to Formulary Chapter 4.4. This will not be first line, but may offer an alternative treatment further down the pathway for the correctly assessed individuals. Note that this is unlicensed in adults. Brand name Elvanse.

Granisetron patches for nausea and vomiting associated with emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days - Chapter 4.6. These should only be used if an oral preparation e.g. ondansetron tablets are unsuitable. Brand name Sancuso.

Rifaximin 550mg tablets for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients \geq 18 years - Chapter 5.1.7. Brand name Targaxan.